PD-L1 couples with LTβR signaling to accelerate regulatory T cell lymphatic migration and tumor metastasis

نویسندگان

چکیده

Abstract Introduction: Tregs in the tumor environment inhibit anti-tumor immunity and are critical targets for strategies. We previously showed that use surface lymphotoxin (LTαβ) PD-1 to signal LTβR PD-L1 on lymphatic endothelial cells, thereby promoting Treg migration. Most cells express PD-L1, yet interactions with LTαβ poorly studied. hypothesized couples signaling tumors regulate migration metastasis. Methods: Wild type CRISPR/Cas9 or knockout B16F10 melanoma were used cell Specific classical nonclassical NFκB blocking peptides used. Results: bound resting B16F10, LTβR-nonclassical increased expression. RNASeq analysis of revealed gene expression regulated by was depletion, while genes driven remained unaltered depletion. Melanoma cocultured had enhanced migration, combined blockade pathways synergistically blocked In vivo, inhibited growth metastases, host survival. Conclusions: Blocking both arms LTβR-NFκB-signaling immune checkpoint efficacy mouse These observations provide a rational strategy modulate activities prevent spread. supported NIH R37 AI062765 Emerald grant 2022

برای دانلود باید عضویت طلایی داشته باشید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

PD-1/PD-L1 signaling in JIA synovial regulatory T cell function

Regulatory T cells (Treg) are key players in the prevention of aberrant immune responses and can be a future therapeutic target in auto-immunity. Tregs can be induced in the periphery by cytokines like TGFb, or in the presence of inhibitory signals provided by antigen presenting cells. The murine programmed death (PD)-1 molecule is known to induce FOXP3 expression by influencing the downstream ...

متن کامل

PD-L1 Expression Is Associated with Tumor FOXP3(+) Regulatory T-Cell Infiltration of Breast Cancer and Poor Prognosis of Patient.

BACKGROUND Expression of PD-L1 has been estimated to predict the therapeutic potential of PD-L1 inhibition in solid tumors. Recent studies have demonstrated that PD-L1 plays a critical role in regulatory T-cell (Treg) development and functional maintenance. Although increases in FOXP3(+)Treg infiltration and PD-L1 expression have been revealed in several malignancies, their correlation in human...

متن کامل

Activation of the PD-1/PD-L1 immune checkpoint confers tumor cell chemoresistance associated with increased metastasis

The ability of tumor cells to avoid immune destruction (immune escape) as well as their acquired resistance to anti-cancer drugs constitute important barriers to the successful management of cancer. Interaction between the Programmed Death Ligand 1 (PD-L1) on the surface of tumor cells with the Programmed Death-1 (PD-1) receptor on cytotoxic T lymphocytes leads to inactivation of these immune e...

متن کامل

Basal cell carcinoma: PD-L1/PD-1 checkpoint expression and tumor regression after PD-1 blockade

Monoclonal antibodies that block immune regulatory proteins such as programmed death-1 (PD-1) have demonstrated remarkable efficacy in controlling the growth of multiple tumor types. Unresectable or metastatic basal cell carcinoma, however, has largely gone untested. Because PD-Ligand-1 (PD-L1) expression in other tumor types has been associated with response to anti-PD-1, we investigated the e...

متن کامل

Tumor endothelial cells accelerate tumor metastasis

Tumor metastasis is the main cause of cancer-related death. Understanding the molecular mechanisms underlying tumor metastasis is crucial to control this fatal disease. Several molecular pathways orchestrate the complex biological cell events during a metastatic cascade. It is now well known that bidirectional interaction between tumor cells and their microenvironment, including tumor stroma, i...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

ژورنال

عنوان ژورنال: Journal of Immunology

سال: 2023

ISSN: ['1550-6606', '0022-1767']

DOI: https://doi.org/10.4049/jimmunol.210.supp.86.09